Pharmacokinetics And Safety Of A Raltegravir-Containing Regimen In Children Aged 4 Weeks To 2 Years Living With Human Immunodeficiency Virus And Receiving Rifampin For Tuberculosis

Paul Krogstad,Pearl Samson,Edward P Acosta,Jack Moye,Ellen Townley,Sarah Bradford,Emily Brown,Kayla Denson,Bobbie Graham,Laura Hovind,Thucuma Sise,Hedy Teppler,Sisinyana Ruth Mathiba,Lee Fairlie,Jana L Winckler,Gretchen Slade,Tammy Meyers

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY（2021）

引用 8|浏览50

暂无评分

摘要

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.

查看译文

关键词

antiretroviral therapy, drug interactions, pediatrics, rifampin, tuberculosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要